Omega Therapeutics Inc (OMGA)

$0.14 -0.02 (-10.82%)
Market Cap 7.90M
Revenue (ttm) 3.09M
Net Income (ttm) -97.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,153.07%
Debt to Equity Ratio 1.35
Volume 5,153,500
Avg Vol 10,728,874
Day's Range N/A - N/A
Shares Out 55.37M
Stochastic %K 22%
Beta 1.65
Analysts Strong Sell
Price Target $11.00
Jmstys245
Jmstys245 Jul. 10 at 7:01 PM
$OMGA welllll????
0 · Reply
prathi88
prathi88 Jul. 9 at 7:50 AM
$OMGA good news are coming soon......
2 · Reply
Jmstys245
Jmstys245 Jul. 8 at 2:47 PM
$OMGA run to $1 let’s goooo
0 · Reply
Jmstys245
Jmstys245 Jul. 8 at 2:21 PM
$OMGA wakey wakeyyyyy
0 · Reply
RhythmGuitar1
RhythmGuitar1 Jul. 7 at 8:59 PM
$OMGA Caveat Emptor Buyer Beware.. PINK SHEET OMGAQ.. Delinquent Reporting Bankruptcy Jussayin.
1 · Reply
TopTier0121
TopTier0121 Jul. 7 at 8:34 PM
$OMGA Any Legit news I got a lot invested and would love any and all updates, I thought they were getting auctioned
0 · Reply
Jmstys245
Jmstys245 Jul. 7 at 6:31 PM
$OMGA wakey wakey eggs and bacyyyyyyy
0 · Reply
RhythmGuitar1
RhythmGuitar1 Jul. 7 at 6:30 PM
$OMGA
0 · Reply
Jmstys245
Jmstys245 Jul. 7 at 6:30 PM
$OMGA wake up folks!!!!!!
0 · Reply
Jmstys245
Jmstys245 Jul. 3 at 4:31 PM
$OMGA
1 · Reply
Latest News on OMGA
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings

Oct 15, 2024, 8:00 AM EDT - 9 months ago

Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Sep 17, 2024, 7:00 AM EDT - 10 months ago

Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications

Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

Omega Therapeutics To Participate In Two Upcoming Investor Conferences

May 30, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics To Participate In Two Upcoming Investor Conferences

Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer

May 29, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

May 8, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 6, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

Mar 31, 2024, 6:22 AM EDT - 1 year ago

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

NVO

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Mar 28, 2024, 9:15 AM EDT - 1 year ago

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024

Mar 6, 2024, 7:00 AM EST - 1 year ago

Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024

Omega Therapeutics: The Next Weight Loss Drug Runner

Jan 16, 2024, 2:10 PM EST - 1 year ago

Omega Therapeutics: The Next Weight Loss Drug Runner

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

Jan 4, 2024, 5:59 AM EST - 1 year ago

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 4:05 PM EST - 1 year ago

Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Dec 4, 2023, 4:00 PM EST - 1 year ago

Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Nov 20, 2023, 4:00 PM EST - 1 year ago

Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Nov 13, 2023, 7:00 AM EST - 1 year ago

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 9, 2023, 7:00 AM EST - 1 year ago

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Omega Therapeutics to Participate in The Jefferies London Healthcare Conference

Nov 7, 2023, 4:00 PM EST - 1 year ago

Omega Therapeutics to Participate in The Jefferies London Healthcare Conference

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

Oct 31, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting® 2023

Oct 11, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting® 2023

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

Oct 6, 2023, 8:26 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

CUTR RVMD VNRX

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 4, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

Sep 26, 2023, 7:00 AM EDT - 1 year ago

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

Sep 25, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

Sep 21, 2023, 4:00 PM EDT - 1 year ago

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

DNLI FHTX MCRB MRNA SANA

Omega Therapeutics Announces Updates to its Board of Directors

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Omega Therapeutics Announces Updates to its Board of Directors

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 3, 2023, 4:00 PM EDT - 2 years ago

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Omega Therapeutics: Working In Epigenetic Anti-Cancer Programs

Aug 1, 2023, 4:29 PM EDT - 2 years ago

Omega Therapeutics: Working In Epigenetic Anti-Cancer Programs

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Jun 21, 2023, 6:00 AM EDT - 2 years ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

DNLI FHTX MCRB MRNA SANA

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

May 31, 2023, 8:30 AM EDT - 2 years ago

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

May 31, 2023, 7:00 AM EDT - 2 years ago

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 4, 2023, 7:00 AM EDT - 2 years ago

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

Apr 27, 2023, 7:00 AM EDT - 2 years ago

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

Mar 30, 2023, 7:00 AM EDT - 2 years ago

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 1, 2023, 7:00 AM EST - 2 years ago

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

Feb 23, 2023, 7:00 AM EST - 2 years ago

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Jan 17, 2023, 7:00 AM EST - 2 years ago

Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium

KSQ Appoints Mahesh Karande to its Board of Directors

Dec 8, 2022, 8:00 AM EST - 2 years ago

KSQ Appoints Mahesh Karande to its Board of Directors

Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 17, 2022, 7:00 AM EST - 2 years ago

Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work

Nov 15, 2022, 7:00 AM EST - 2 years ago

Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work

Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 8, 2022, 7:00 AM EST - 2 years ago

Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Omega Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 3, 2022, 7:00 AM EDT - 2 years ago

Omega Therapeutics to Participate in the Jefferies London Healthcare Conference

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

Nov 2, 2022, 7:00 AM EDT - 2 years ago

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

Jmstys245
Jmstys245 Jul. 10 at 7:01 PM
$OMGA welllll????
0 · Reply
prathi88
prathi88 Jul. 9 at 7:50 AM
$OMGA good news are coming soon......
2 · Reply
Jmstys245
Jmstys245 Jul. 8 at 2:47 PM
$OMGA run to $1 let’s goooo
0 · Reply
Jmstys245
Jmstys245 Jul. 8 at 2:21 PM
$OMGA wakey wakeyyyyy
0 · Reply
RhythmGuitar1
RhythmGuitar1 Jul. 7 at 8:59 PM
$OMGA Caveat Emptor Buyer Beware.. PINK SHEET OMGAQ.. Delinquent Reporting Bankruptcy Jussayin.
1 · Reply
TopTier0121
TopTier0121 Jul. 7 at 8:34 PM
$OMGA Any Legit news I got a lot invested and would love any and all updates, I thought they were getting auctioned
0 · Reply
Jmstys245
Jmstys245 Jul. 7 at 6:31 PM
$OMGA wakey wakey eggs and bacyyyyyyy
0 · Reply
RhythmGuitar1
RhythmGuitar1 Jul. 7 at 6:30 PM
$OMGA
0 · Reply
Jmstys245
Jmstys245 Jul. 7 at 6:30 PM
$OMGA wake up folks!!!!!!
0 · Reply
Jmstys245
Jmstys245 Jul. 3 at 4:31 PM
$OMGA
1 · Reply
Jmstys245
Jmstys245 Jun. 10 at 2:53 PM
$OMGA this gonna run out of nowhere unexpectedly watch….
0 · Reply
ooio
ooio Jun. 9 at 8:57 AM
$OMGA
1 · Reply
Jmstys245
Jmstys245 Jun. 2 at 11:00 PM
$OMGA is this stock still trading? ???
0 · Reply
Jmstys245
Jmstys245 May. 16 at 3:47 PM
$OMGA about to runnnnn yall Were alerted early
0 · Reply
Jmstys245
Jmstys245 May. 9 at 11:13 AM
$OMGA
0 · Reply
Jmstys245
Jmstys245 May. 8 at 9:29 PM
$OMGA any updates?????
0 · Reply
Jmstys245
Jmstys245 May. 8 at 4:38 PM
$OMGA any updates????
0 · Reply
HarryA123
HarryA123 May. 6 at 3:44 PM
$OMGA This may be interesting?? There is an article today, https://www.prnewswire.com/news-releases/ousia-pharma-secures-substantial-seed-financing-led-by-omega-funds-to-advance-groundbreaking-obesity-treatment-302446447.html Omega Funds is a major investor in Omega Therapeutics.
0 · Reply
Jmstys245
Jmstys245 Apr. 30 at 4:57 PM
$OMGA any updates!!???????
0 · Reply
Jmstys245
Jmstys245 Apr. 30 at 4:30 PM
$OMGA any updates people!!!!??????
0 · Reply
HarryA123
HarryA123 Apr. 29 at 5:51 AM
$OMGA https://cases.ra.kroll.com/omega/Home-DocketInfo
1 · Reply
Jmstys245
Jmstys245 Apr. 29 at 1:45 AM
$OMGA updates????????
0 · Reply